Zydus Saroglitazar Mg To Treat Primary Biliary Cholangitis Receives Us Fda Orphan Drug Designation

Zydus Saroglitazar Mg To Treat Primary Biliary Cholangitis Receives Us Fda Orphan Drug Designation

By, Admin 29 January 2021

Zydus, A Leading Discovery Based, Global Pharmaceutical Company, Announced That United States Food And Drug Administration (Fda) Has Granted &Lsquo;Orphan Drug Designation&Rsquo; (Odd) To Saroglitazar Mg For The Treatment Of Patients With Primary Biliary Cholangitis (Pbc).Orphan Drug Designation Provides Eligibility For Certain Development Incentives, Including Tax Credits For Qualified Clinical Testing, Prescription Drug User Fee Exemptions And Seven-Year Marketing Exclusivity Upon Fda Approval. This Follows The Grant Of &Lsquo;Fast Track Designation&Rsquo; By The Us Fda To Saroglitazar Mg For Pbc In December 2020.Saroglitazar Mg Is A Potent And Selective Peroxisome Proliferator-Activated Receptor Alpha And Gamma Dual Agonist. Results Of Phase 2, Prospective Multicentre Randomized Double-Blind, Placebo Controlled Study To Evaluate The Safety, Tolerability And Efficacy Of Saroglitazar Mg In Patients With Primary Biliary Cholangitis (Epics) Was Presented Earlier At The Liver Meeting 2020, The Annual Meeting Of The American Association For The Study Of Liver Diseases (Aasld) [Clinicaltrials.Gov Identifier: Nct03112681].The Treatment Options Are Still Evolving For Pbc And Saroglitazar Holds Immense Potential Based On Its Safety And Efficacy Profile So Far. The Global Market For Pbc Treatment Is Expected To Grow At A Cagr Of 36.3% From 2018 &Ndash; 2026 And Is Expected To Reach Us$ 10.8 Billion By 2026 As Per Coherent Market Insights.Pankaj R Patel, Chairman, Zydus Group Said, &Ldquo;We Are Pleased That The Us Fda Has Granted An Orphan Drug Designation Apart From The Earlier Fast Track Designation To Saroglitazar Mg For The Treatment Of Primary Biliary Cholangitis. This Underlines The Urgent Need To Address This Serious Health Condition Which Is An Unmet Medical Need. We Are Committed In Our Clinical Development Efforts To Improve The Quality Of Life Of Patients Suffering From Pbc With A Safe And Efficacious Treatment.&Rdquo;

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!